May 30 2022 Castle Creek Biosciences raises US $112.8 million
Castle Creek Biosciences raised US $112.8 million in its latest round of preferred stock financing.
The financing is expected to advance Castle Creek’s cell and gene therapy pipeline, including funding the completion of a Phase III study of D-Fi, a cell-based gene therapy delivered by local injection, which addresses Collagen VII deficiency in patients with dystrophic EB.
Read more in Castle Creek Biosciences’ press release.
